LBA23 - MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)

S.M Tolaney,A.M Wardley,S Zambelli,J Hilton,T Troso-Sandoval,F Ricci,S.-A Im,S.-B Kim,S.R.D Johnston,A Chan,S Goel,K Catron,Z Yang,C Gainford,F André

doi:10.1093/annonc/mdz394.012

LBA23 - MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)

S.M Tolaney, A.M Wardley + Show 13 more

Open Access

https://doi.org/10.1093/annonc/mdz394.012

Copy DOI

Journal: Annals of Oncology	Publication Date: Oct 1, 2019
Citations: 19

Affiliation: Dana-Farber Cancer Institute, University of Manchester, Ottawa Hospital, Seoul National University Hospital, Asan Medical Center, Royal Marsden Hospital

#Research Grant #Funding Institution + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

LBA23 - MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.